Dan Moore became President and Chief Executive Officer of Cyberonics in 2007. During the first five years of his tenure, the Company resumed meaningful epilepsy revenue growth and quickly returned to significant profitability after multiple years of losses. Net sales for fiscal year 2012 were $219 million resulting in income from operations of $61 million. Under the direction of Mr. Moore and his senior management team, Cyberonics is focused on its core expertise in neuromodulation, other medical devices for epilepsy, and expanding the Vagus Nerve Stimulation (VNS) Therapy® franchise, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.
Mr. Moore joined Cyberonics from Boston Scientific where, since 1989, he held positions in sales, marketing and senior management in the United States and in Europe. In his last position at Boston Scientific, he served as President, International Distributor Management. Prior to this position, he was President, Inter-Continental, the fourth largest business unit of Boston Scientific with more than 1,000 global employees and revenues exceeding $700 million. Mr. Moore began his career with Procter and Gamble after graduating from Harvard College. He also earned an MBA from Boston University.
In addition to Cyberonics, he serves on the boards of BrainScope Company, Inc., Trivascular, Inc.,
BioHouston Executive Committee, Weldon School of Biomedical Engineering at Purdue University, the Medical Device Innovation Consortium (MDIC), the Epilepsy Foundation of Texas (immediate past-Chair), the Epilepsy Foundation of Texas - Houston (immediate past-President) and the Epilepsy Foundation of America®. He currently serves as the Chairman of the Board of Directors of the Medical Device Manufacturers Association (MDMA).